View Article |
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Jean-François Rossi1.
Cancer cell growth is associated to an immune surveillance failure. The aim to restore an immune control of cancer cells represents an important therapeutic development. Nowadays, immune therapy is improving, due to the recent advances in biological knowledge. One of the most important successes in immune therapy is represented by mono-clonal antibodies, particularly the use of rituximab for B-cell lymphoproliferative disorders. More recently, other monoclonal antibodies have been developed, to inhibit immune checkpoints within the tumor microenvironment that limit immune suppression, or to enhance some immune functions with immune adjuvants through different targets such as Toll-receptor agonists. The aim is to inhibit cancer growth proliferation, a situation that could be bio-logically measured by the diminishing/elimination of cancer residual cells, and clinically by improving the response duration with no or few adverse effects. This effect is supported by enhancing the number, functions, and activity of the immune effector cells (IEC), including the natural killer (NK) lymphocytes, NKT-lymphocytes, γδ T-lymphocytes, cytotoxic T-lymphocytes; directly or indirectly through vaccines particularly with Neoantigens, and by lowering the functions of the immune suppressive cells. Beyond these new therapeutics and their personalized usage, new con-siderations have to be taken into account, such as epigenetic regulation particularly from microbiota, evaluation of transversal functions, particularly cellular metabolism, and consideration to the clinical consequences at the body level. We plan to discuss these fundamentals, defining simple questions, how, and when to use immune therapeutic tools to support activation, amplification or administration of IEC that control or eradicate tumor cells. In addition, there is a place for a biological dynamic follow-up including the initial inflammatory response, biomarkers for both immune activation and immune exhaustion in order to adapt and to adopt Immune Precision Medicine approach.
Affiliation:
- University of Montpellier, France
|
|
Indexation |
Indexed by |
MyJurnal (2021) |
H-Index
|
3 |
Immediacy Index
|
0.000 |
Rank |
0 |
Indexed by |
Scopus 2020 |
Impact Factor
|
CiteScore (0.2) |
Rank |
Q4 (Medicine (all)) |
Additional Information |
SJR (0.144) |
|
|
|